Analyst Price Target is $5.50
▲ +208.99% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for SELLAS Life Sciences Group in the last 3 months. The average price target is $5.50, with a high forecast of $8.00 and a low forecast of $3.00. The average price target represents a 208.99% upside from the last price of $1.78.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in SELLAS Life Sciences Group. This Buy consensus rating has held steady for over two years.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.